CurrentCignaPolicy 0057

Mammary Ductoscopy, Aspiration and Lavage

This policy governs coverage for mammary ductoscopy, ductal lavage, and mammary duct aspiration using non‑invasive collection devices for breast cancer screening, evaluation of pathologic nipple discharge, and intraoperative guidance; it applies to services submitted to Cigna-administered health benefit plans.

Policy Summary

PayerCigna

PolicyMammary Ductoscopy, Aspiration and Lavage

Policy CodePolicy 0057

Change TypeAnnual review — no clinical statement changes

Effective Date

Next Review DateJan 15, 2026

Key ActionWhen billing, use the most appropriate current procedure codes; procedures considered experimental/investigational (e.g., ductoscopy, ductal lavage, non‑invasive aspiration) are not supported for coverage and may be denied or require prior review.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3experimental procedures

19499example unlisted code

20meta-analysis studies

2years no policy changes

2026-01-15annual review

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria

Not medically necessary / Experimental

Overall coverage stance: Mammary ductoscopy, ductal lavage, and mammary duct aspiration by non‑invasive collection devices are considered experimental, investigational or unproven for any indication.

Supported by evidence limitations and policy statement in the coverage policy.

Mammary ductoscopy - diagnostic use

Covered when ALL of the following are met:

MD_for_pathologic_nipple_discharge: Mammary ductoscopy may be considered in the diagnostic evaluation of patients with spontaneous, bloody or serous nipple discharge persisting >2 months (pathologic nipple discharge) when standard imaging (mammography and ultrasound) is non-diagnostic and intraductal visualization could inform management.

Evidence is limited to case series; while some cohorts report high sensitivity for cancer detection with nipple discharge, randomized trials and comparative outcomes data are lacking.

Ductal lavage - screening/risk assessment

Not covered / Not medically necessary when ANY of the following are present:

DL_for_routine_screening_or_risk_stratification: Ductal lavage used for routine breast cancer screening, for risk stratification in asymptomatic or high‑risk patients, or for biomarker surveillance is not medically necessary due to inconsistent cell yield, poor reproducibility, and lack of demonstrated impact on clinical outcomes.

Published studies report wide ranges of sensitivity/specificity, high rates of insufficient cellular material, and poor reproducibility over time.

Non-invasive collection devices

Non-invasive_collection_devices: Non‑invasive mammary duct aspiration collection devices (e.g., Halo Breast Pap Test [K020848], MASCT [K030443]) are FDA 510(k)-cleared but lack robust peer‑reviewed evidence demonstrating clinical benefit for breast cancer screening; their use for routine screening or as a replacement for established screening methods is not supported.

Manufacturer-sponsored and observational studies report low fluid production rates and a high proportion of samples with insufficient cellularity; randomized controlled data and long‑term outcomes are lacking.

Mammary ductoscopy, ductal lavage of the mammary ducts, and mammary duct aspiration by a non‑invasive collection device (for example, HALO Breast Pap Test or MASCT System) are designated as experimental, investigational, or unproven for any indication. These procedures are not supported for coverage because available evidence is limited and does not establish clinical utility or improvement in health outcomes.

Authoritative guidance from practice groups cited in the evidence review does not support ductal lavage for screening. The National Cancer Institute PDQ notes that proposed methods including ductal lavage have not been shown to reduce mortality, and the National Comprehensive Cancer Network (NCCN) explicitly does not recommend the use of ductal lavage as a screening procedure or for diagnosis (NCCN, 2025). These statements support the policy position that ductal lavage is not appropriate for routine screening.

The reviewed document chunks do not include additional explicit exclusions beyond the statement that these procedures are considered experimental, investigational or unproven. No separate, itemized exclusion list for specific clinical scenarios is provided in the cited sections of the source document.

Use of mammary ductoscopy, ductal lavage, or non‑invasive mammary duct aspiration devices for breast cancer screening, for evaluation of pathologic nipple discharge as a routine diagnostic substitute for standard imaging, or for intraoperative guidance during breast-conserving procedures is designated investigational/unproven in this policy. The evidence base is limited to case series and small observational studies; benefit over established diagnostic and surgical guidance techniques is not established.

Ductal lavage is not considered medically necessary for routine risk stratification, screening, or biomarker surveillance because studies report inconsistent cell yield, variable sensitivity and specificity (reported ranges include 17%–83.8% sensitivity and 64%–100% specificity), frequent inadequate samples, poor reproducibility, and no clear correlation with subsequent cancer risk. Available data do not demonstrate that ductal lavage improves screening outcomes or clinical management.

The source material does not present standalone statements labeled explicitly as 'not medically necessary' beyond the overall designation of these procedures as experimental, investigational, or unproven. The policy language relies on that investigational designation and the supporting evidence summary rather than separate 'not medically necessary' declarations in the cited chunks.

Covered Indications

Screening, pathological nipple discharge evaluation, intraoperative guidance

Investigational indications: Screening for breast cancer, evaluation of pathologic nipple discharge, and intraoperative guidance during breast‑conserving surgery are proposed indications for mammary ductoscopy, ductal lavage, and related procedures but are considered investigational per this policy.

See policy overview and investigational list identifying these procedures as experimental/unproven.

Pathologic nipple discharge with non-diagnostic imaging

Pathologic_nipple_discharge_indication: Patients with spontaneous, bloody or serous nipple discharge persisting more than two months (pathologic discharge) in whom mammography and ultrasound are non‑diagnostic and further intraductal evaluation is being considered.

Case series demonstrate ductoscopy can visualize intraductal lesions in many patients, but comparative diagnostic accuracy and impact on management are not established.

Pathologic nipple discharge and diagnostic evaluation of intraductal breast lesions

Coding

Considered Experimental/Investigational/Unproven codesCPTNot Covered

19499

Unlisted procedure, breast

Example FDA 510(k) device identifiersmixed

K020848	Halo Breast Pap Test system (NAFD 100) - FDA 510(k) identifier
K030443	Mammary Aspiration Specimen Cytology Test (MASCT) System - FDA 510(k) identifier

Provider Actions & Billing Notes

Billing Rule

Billing guidance

Claims submitted for services that are not accompanied by covered code(s) under the applicable Coverage Policy will be denied as not covered. Providers must ensure claims use codes that are valid and active as of the date of submission; deleted or inactive codes may not be eligible for reimbursement.

Claims with codes not listed as covered may be denied
Deleted or inactive codes at time of service may not be accepted

Denial Risk

Denial risk — Ductal Lavage (DL) as screening

Ductal lavage (DL) is not supported as an effective screening tool for breast cancer based on available evidence. Claims for DL when billed as a screening service or routine breast cancer screening may be denied due to lack of demonstrated clinical utility.

Prior Authorization

Non‑invasive mammary duct aspiration devices — use for routine screening may require review

Use of non‑invasive mammary duct aspiration collection devices for routine screening or other nonstandard indications may require review prior to service because evidence of clinical benefit is lacking.

Devices cited as examples: Halo (K020848) and MASCT (K030443).
Manufacturer‑sponsored studies report low rates of adequate cytology and limited correlation with risk profiles.

Not Covered / Not Medically Necessary

Mammary ductoscopy for screening, ductal lavage for screening or diagnostic evaluation, and mammary duct aspiration by non‑invasive collection devices are not covered because they are considered experimental, investigational, or unproven. Ductal lavage and nipple‑aspirate–based screening are specifically not supported as screening options for asymptomatic patients or as alternatives to established breast cancer screening modalities given lack of demonstrated clinical benefit and inconsistent diagnostic performance.

Ductal lavage and nipple aspirate–based screening procedures are not covered when proposed for asymptomatic screening or as an alternative to established screening methods. Professional guidance and the reviewed studies do not support DL for routine population screening because of limited sensitivity/specificity, frequent inadequate samples, and lack of evidence showing reduced mortality or improved patient outcomes.

Background

Mammary ductoscopy is an endoscopic technique involving direct visualization of the mammary ducts using a rigid or fiberoptic ductoscope; it has been proposed for evaluation of pathologic nipple discharge, to localize intraductal lesions, and to potentially guide duct excision or breast‑conserving surgery. Ductal lavage and non‑invasive mammary duct aspiration devices are methods to obtain ductal epithelial cells or nipple aspirate fluid for cytologic analysis or biomarker assessment, but cellular yield, reproducibility, and clinical utility have not been established in controlled studies.

Definitions

inv-26: Mammary ductoscopy (MD) — definition and alternate terms

DefinitionDirect endoscopic visualization of the mammary ducts using a rigid or fiberoptic ductoscope (also called fiberoptic ductoscopy or breast duct endoscopy).

Alternate termsFiberoptic ductoscopy; breast duct endoscopy; ductoscopy; MD (mammary ductoscopy).

Key limitationLimited visualization of smaller peripheral ducts and terminal duct-lobular units due to scope diameter; limited biopsy capability.

inv-27: Ductal lavage and mammary duct aspiration — definition and intended purpose

DefinitionProcedures to extract nipple aspirate fluid either by intraductal lavage (invasive) or by non‑invasive mammary duct aspiration collection devices for cytologic evaluation.

Intended purpose

References & Revision History

2026-01-15annual_reviewLatest

Annual review completed; no clinical policy statement changes documented.

2025editorial_revision

Policy wording revised for readability (not a clinical policy statement change).

2024annual_review

Policy Summary

PayerCigna

PolicyMammary Ductoscopy, Aspiration and Lavage

Policy CodePolicy 0057

Change TypeAnnual review — no clinical statement changes

Effective Date

Next Review DateJan 15, 2026

SourceLink

On This Page

PND_and_intraductal_evaluation: Evaluation of pathologic nipple discharge and diagnostic assessment of intraductal breast lesions (including visualization, localization, and use during resection) have been described in the literature but lack randomized controlled evidence to establish clinical utility.

References include multiple case series and observational studies; interventional ductoscopy and localization techniques have been reported but evidence is limited.

Denial risk for DL when used for screening or routine screening purposes
DL may be feasible for sampling but clinical utility for screening is unproven

Documentation Required

Provider billing actions

Claims submitted with codes not listed as covered under this Coverage Policy are at risk for denial. When billing, providers must use the most appropriate and current codes effective on the date of submission. Documentation should include rationale and supporting clinical information when nonstandard or investigational procedures are billed.

Use current, appropriate CPT/HCPCS/ICD-10 codes effective on date of service
Claims with codes not listed as covered may be denied
Deleted codes may not be eligible for reimbursement

Prior Authorization

Prior authorization / device documentation

Mammary ductoscopy, ductal lavage, and non-invasive mammary duct aspiration collection devices are considered experimental, investigational or unproven for any indication per this policy. Prior authorization may be required when nonstandard or investigational use is requested; document device identification and indication for use when applicable. FDA clearance alone does not guarantee coverage.

Procedures listed as experimental/investigational/unproven may require prior authorization if requested
Document device identification, manufacturer, and indication for use when billing
FDA 510(k) clearance does not by itself indicate coverage

Step Therapy

Step therapy

Not applicable in the document excerpt: there are no specified step therapy rules for these procedures in this policy.

Step therapy: Not applicable / none specified

Note

Annual review / policy continuity

Annual review notes: the policy summary indicates no clinical policy statement changes in the most recent annual review. Providers should follow existing policy language for coverage determinations and document services accordingly.

Annual review: No clinical policy statement changes in recent reviews
Document annual review awareness in case management or prior authorization records

Proposed for breast cancer screening, risk assessment/stratification, and evaluation of women who produce nipple fluid or have nipple discharge.

Evidence summaryInsufficient peer-reviewed evidence to support clinical effectiveness for screening; prospective randomized studies are lacking.

inv-28: Ductal lavage (DL) — invasive intraductal sampling technique definition and reported sensitivity range

DefinitionAn invasive intraductal sampling technique that uses saline irrigation to obtain ductal epithelial cells for cytologic analysis (ductal lavage, DL).

Reported sensitivity rangePublished sensitivity range reported as approximately 17% to 83.8% for identification of intraductal abnormalities or cancer.

Reported specificity rangeReported specificity ranges from about 64% to 100%; cellular yield and reproducibility are inconsistent.

inv-29: Mammary ductoscopy (MD) — fiberoptic visualization definition and potential uses

DefinitionFiberoptic visualization of breast ducts to identify intraductal abnormalities using a ductoscope; may guide duct excision or breast-conserving surgery in selected cases.

Potential usesDiagnostic evaluation of pathologic nipple discharge, intraoperative guidance for duct incision or lesion localization, and attempted improvement in detection of intraductal lesions when standard imaging is non-diagnostic.

Evidence limitationsEvidence is primarily from uncontrolled case series; specificity, PPV, and long-term outcome data are limited and clinical utility is not established.

inv-30: Non-invasive mammary duct aspiration collection devices — office-based devices and FDA 510(k) clearance mention

Office-based devices (examples)Halo Breast Pap Test system (Identifier K020848) and Mammary Aspirate Specimen Cytology Test (MASCT) System (Identifier K030443).

Regulatory statusThese non-invasive mammary duct aspiration collection devices are Class II medical devices cleared by the FDA via the 510(k) pathway (product code KNW).

Intended useCollect nipple aspirate fluid in an office setting for cytologic evaluation to differentiate normal, premalignant, and malignant cells (per device indications).

inv-31: ductoscopy / mammary ductoscopy — alternative definition from references segment

Alternative definitionEndoscopic evaluation of breast ducts to detect intraductal lesions in patients with pathologic nipple discharge; may be termed ductoscopy or mammary ductoscopy in the literature.

Primary clinical contextUsed in studies for evaluation and management of pathologic nipple discharge and to potentially avoid unnecessary duct excision.

Reference noteMultiple case series and comparative studies are cited in the references supporting this usage (references listed in policy).

inv-32: ductal lavage — definition from references segment

Reference definitionCytologic sampling of ductal epithelial cells via lavage for detection or risk assessment of breast cancer; described in the literature as ductal lavage (DL).

Methodological noteDL provides duct‑specific sampling but may dilute biomarkers because of saline irrigation and has variable cellular yield and reproducibility.

Clinical evidenceStudies and reviews cited highlight inconsistent sensitivity/specificity and lack of evidence demonstrating DL reduces breast cancer mortality or improves outcomes.

inv-33: nipple aspirate / nipple aspirate fluid — definition and cytology

DefinitionNipple aspirate fluid (NAF) is the fluid obtained from the nipple via noninvasive aspiration or lavage for cytomorphologic analysis (nipple aspirate/nipple aspirate fluid).

Cytology useCytologic evaluation of NAF has been investigated as a risk assessment tool; abnormal cytology or presence of epithelial cells has been associated with increased relative risk in some uncontrolled studies.

LimitationsHigh rates of inadequate samples and lack of prospective randomized data limit its clinical utility for routine screening or risk stratification.

Annual review completed; no clinical policy statement changes documented.

2025-11-25reference_update

FDA 510(k) database and guideline references accessed/updated in the reference list (FDA 510(k) and NCI/NCCN guideline entries).

Most recent annual review: 1/15/2026. The policy record indicates no clinical policy statement changes during the 2024 and 2026 reviews and a wording revision in 2025 to improve readability. The next scheduled review date is noted as 2026‑01‑15 in the policy metadata.